Dr. Frank Luh to Speak at ISPE LA Executive Night 2025
Dr. Frank Luh, CEO of the Sino-American Cancer Foundation (SACF), will speak at the ISPE Greater Los Angeles Chapter's Executive Night 2025, hosted by Takeda in March 2025.A leader in…
laura biganzoli’s Latest Contributions to Breast Cancer & Geriatric Oncology
Dr. laura biganzoli continues to drive impactful research in breast cancer and geriatric oncology.In September 2024, she co-authored a study in the New England Journal of Medicine showing that trastuzumab…
RIGHT Choice Trial: Ribociclib + Endocrine Therapy vs. Chemotherapy in HR+/HER2– Advanced Breast Cancer
In August 2024, Dr. Nagi El Saghir and colleagues published a key subgroup analysis from the RIGHT Choice Trial, comparing first-line ribociclib (RIB) plus endocrine therapy (ET) to combination chemotherapy…
Dr. Hua Zhong and Dr. Baohui Han on the Efficacy and Safety of Sacituzumab Govitecan in Extensive-Stage Small Cell Lung Cancer
The rapid advancements in modern oncology have introduced numerous breakthrough treatment options for lung cancer, making it one of the fastest-evolving solid tumors. To help clinicians gain an in-depth and comprehensive understanding of major developments in this field, Oncology Frontier has collaborated with Dr. Hua Zhong and Dr. Baohui Han from the Department of Respiratory and Critical Care Medicine at Shanghai Chest Hospital to launch a clinical progress series—"Zhong" Sound "Hui" Words. Through in-depth analyses of high-quality clinical studies in lung cancer, this series aims to enhance clinical decision-making and treatment practices.
ASCO GU 2025 | Dr. Hongqian Guo’s Team from Nanjing Drum Tower Hospital Shares Multiple Breakthroughs in Urological Oncology
The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) was held from February 13 to 15 in San Francisco, showcasing the latest research and treatment strategies in the field of urological oncology from experts worldwide. Several clinical research findings from Dr. Hongqian Guo’s team at Nanjing Drum Tower Hospital were selected for presentation, covering a wide range of topics, including non-clear cell renal cell carcinoma (nccRCC), small renal tumors, metastatic hormone-sensitive prostate cancer (mHSPC), upper tract urothelial carcinoma (UTUC), and bladder cancer. Urology Frontier invited Professors Xuefeng Qiu, Shun Zhang, Guangxiang Liu, Yifan Sun, and Dr. Xi Zheng from Nanjing Drum Tower Hospital to share their insights.
NeoSTAR Trial: Sacituzumab Govitecan in Early-Stage TNBC
The NeoSTAR trial, published in March 2024, evaluated neoadjuvant sacituzumab govitecan (SG) in early-stage triple-negative breast cancer (TNBC). This study explored a response-guided approach using SG alone for four cycles.…
Dr. Peng Zhang: The HOPE Series Study Results Announced – ADC Combined Immunotherapy Brings New Hope for Bladder Preservation in MIBC Patients
Currently, chemotherapy combined with immunotherapy for bladder preservation has met the clinical needs of some muscle-invasive bladder cancer (MIBC) patients, offering a potential balance between effective tumor control and improved quality of life. However, for MIBC patients who are intolerant to platinum-based chemotherapy, bladder-preserving strategies still require further exploration. At the recently held ASCO-GU Annual Meeting, Dr. Peng Zhang’s team from West China Hospital, Sichuan University, presented the HOPE series studies, among which the HOPE 03 study showcased the efficacy of ADC combined with immunotherapy in bladder preservation for MIBC patients. Urology Frontier invited Professor Zhang to share the key highlights of this research.